

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

SECTION 1. IDENTIFICATION

Product name : LSS CLINICAL ANTIPERSPIRANT POWDER
B06564860000

Product code : 200000073450

Manufacturer or supplier's details

Company name of supplier : Colgate-Palmolive Co
300 Park Avenue
New York, NY 10022

Telephone : US: Consumer Affairs - 1-800-468-6502

Emergency telephone number : For emergencies involving spill, leak, fire, exposure or accident call CHEMTREC (24hr) at (800) 424-9300 or (703) 527-3887.

Global-CHEMTREC- +1 703-741-5970

Recommended use of the chemical and restrictions on use

Recommended use : A formulated deodorant / antiperspirant roll-on

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

Other hazards

None known.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**Components**

Chemical name	CAS-No.	Concentration (% w/w)
DECAMETHYLCYCLOPENTASILOXANE	541-02-6	$\geq 10 - \leq 30$
ALUMINUM ZIRCONIUM	90604-80-1	$\geq 7 - \leq 13$

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

TETRACHLOROHYDREX GLY		
PPG-14 BUTYL ETHER	9003-13-8	$\geq 3 - \leq 7$
2-Benzylideneoctanal	101-86-0	$\geq 0.1 - \leq 1$
Tetrahydrolinalool	78-69-3	$\geq 0.1 - \leq 1$
HEXYL SALICYLATE	6259-76-3	$\geq 0.1 - \leq 1$

SECTION 4. FIRST AID MEASURES

General advice	:	Do not leave the victim unattended.
If inhaled	:	If unconscious, place in recovery position and seek medical advice. If symptoms persist, call a physician.
In case of skin contact	:	If skin irritation persists, call a physician. If on skin, rinse well with water. If on clothes, remove clothes.
In case of eye contact	:	Flush eyes with water as a precaution. Remove contact lenses. Protect unharmed eye. Keep eye wide open while rinsing. If eye irritation persists, consult a specialist.
If swallowed	:	Keep respiratory tract clear. Never give anything by mouth to an unconscious person. If symptoms persist, call a physician.
Most important symptoms and effects, both acute and delayed	:	None known.
Notes to physician	:	Treat symptomatically.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Unsuitable extinguishing media	:	High volume water jet
Specific hazards during fire-fighting	:	Do not allow run-off from fire fighting to enter drains or water courses.
Hazardous combustion prod-	:	No hazardous combustion products are known

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version 1.0	Revision Date: 02/20/2025	SDS Number: 660000021487	Date of last issue: - Date of first issue: 02/20/2025
----------------	------------------------------	-----------------------------	--

ucts

Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains. Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Avoid dust formation. Avoid breathing dust.

Environmental precautions : Prevent product from entering drains. Prevent further leakage or spillage if safe to do so. If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Avoid dust formation. Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : Avoid contact with skin and eyes. For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area. Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Electrical installations / working materials must comply with the technological safety standards.

Further information on storage stability : No decomposition if stored and applied as directed.

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
DECAMETHYLCYCLOPENTA SILOXANE	541-02-6	TWA	10 ppm	US WEEL
ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY	90604-80-1	TWA	5 mg/m ³ (Zirconium)	OSHA Z-1
		TWA	5 mg/m ³ (Zirconium)	ACGIH
		STEL	10 mg/m ³ (Zirconium)	ACGIH
		TWA	5 mg/m ³ (Zirconium)	OSHA P0
		STEL	10 mg/m ³ (Zirconium)	OSHA P0
		TWA	5 mg/m ³ (Zirconium)	NIOSH REL
		STEL	10 mg/m ³ (Zirconium)	NIOSH REL

Personal protective equipment

Hand protection

Remarks : The suitability for a specific workplace should be discussed with the producers of the protective gloves.

Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles

Skin and body protection : Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Hygiene measures : When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Solid

Colour : off-white, light yellow

Odour : No data available

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

pH : No data available

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : No data available

Solubility(ies)
Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No decomposition if stored and applied as directed.

Chemical stability : No decomposition if stored and applied as directed.

Possibility of hazardous reactions : No decomposition if stored and applied as directed.

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

Conditions to avoid	:	No data available
Incompatible materials	:	Not applicable
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	--

Acute dermal toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
-----------------------	---	--

Components:**ALUMINUM ZIRCONIUM TETRACHLOROXYDREX GLY:**

Acute oral toxicity	:	Remarks: Not applicable
---------------------	---	-------------------------

Acute inhalation toxicity	:	Remarks: Not applicable
---------------------------	---	-------------------------

Acute dermal toxicity	:	Remarks: Not applicable
-----------------------	---	-------------------------

PPG-14 BUTYL ETHER:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
---------------------	---	---------------------------

Acute inhalation toxicity	:	Remarks: No data available
---------------------------	---	----------------------------

Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: No information available.
-----------------------	---	--

2-Benzylideneoctanal:

Acute oral toxicity	:	LD50 (Rat): 2,000 mg/kg
---------------------	---	-------------------------

HEXYL SALICYLATE:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
---------------------	---	---------------------------

Acute inhalation toxicity	:	Remarks: No data available
---------------------------	---	----------------------------

Acute dermal toxicity	:	LD50 (Rabbit): > 5,000 mg/kg Method: No information available.
-----------------------	---	---

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

Skin corrosion/irritation

Not classified based on available information.

Components:**DECAMETHYLCYCLOPENTASILOXANE:**

Result : No skin irritation

ALUMINUM ZIRCONIUM TETRACHLOROXYDREX GLY:

Result : Mild skin irritation

PPG-14 BUTYL ETHER:

Result : Mild skin irritation

Remarks : May cause skin irritation and/or dermatitis.

2-Benzylideneoctanal:

Result : Mild skin irritant

Remarks : May cause skin irritation and/or dermatitis.

Tetrahydrolinalool:

Remarks : May cause skin irritation and/or dermatitis.

HEXYL SALICYLATE:

Species : Rabbit

Result : Irritating to skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**DECAMETHYLCYCLOPENTASILOXANE:**

Result : No eye irritation

ALUMINUM ZIRCONIUM TETRACHLOROXYDREX GLY:

Result : No eye irritation

PPG-14 BUTYL ETHER:

Result : Mild eye irritation

Remarks : Vapours may cause irritation to the eyes, respiratory system and the skin.

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

2-Benzylideneoctanal:

Result : No eye irritation

Remarks : Vapours may cause irritation to the eyes, respiratory system and the skin.

Tetrahydrolinalool:

Remarks : May cause irreversible eye damage.

HEXYL SALICYLATE:

Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**DECAMETHYLCYCLOPENTASILOXANE:**

Exposure routes : Inhalation

Result : Does not cause respiratory sensitisation.

Exposure routes : Dermal

Result : Does not cause skin sensitisation.

ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY:

Exposure routes : Inhalation

Result : Does not cause respiratory sensitisation.

Exposure routes : Dermal

Result : Does not cause skin sensitisation.

PPG-14 BUTYL ETHER:

Exposure routes : Inhalation

Remarks : No data available

Exposure routes : Dermal

Result : Does not cause skin sensitisation.

2-Benzylideneoctanal:

Exposure routes : Inhalation

Remarks : No data available

Exposure routes : Dermal

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version 1.0	Revision Date: 02/20/2025	SDS Number: 660000021487	Date of last issue: - Date of first issue: 02/20/2025
----------------	------------------------------	-----------------------------	--

Result : May cause sensitisation by skin contact.

Remarks : Causes sensitisation.

Tetrahydrolinalool:

Exposure routes : Inhalation

Remarks : No data available

Remarks : Causes sensitisation.

HEXYL SALICYLATE:

Exposure routes : Inhalation

Remarks : No data available

Exposure routes : Dermal

Result : May cause sensitisation by skin contact.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

IARC

No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Aspiration toxicity

Not classified based on available information.

Further information

Product:

Remarks : This product has not been tested as a whole. However, this formula was reviewed by expert toxicologists in the Product Safety Assurance Department of Colgate-Palmolive and is

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

determined to be safe for its intended use. This review has taken into consideration available safety-related information including information on individual ingredients, similar formulas and potential ingredient interactions. This review is a component of the hazard determination used to prepare the statements in Section 2 of the SDS.

SECTION 12. ECOLOGICAL INFORMATION

The product has not been tested as a whole for environmental toxicity. However, environmental information on the ingredients in this product have been reviewed by the Environmental Occupational Health and Safety group of Colgate-Palmolive and determined to have an acceptable environmental profile. This evaluation is based on available information on individual ingredients, interactions of ingredients, and similar ingredients. Biodegradability claims are supported by data on ingredients (i.e., surfactants are biodegradable).

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	The product should not be allowed to enter drains, water courses or the soil. Do not contaminate ponds, waterways or ditches with chemical or used container. Send to a licensed waste management company.
Contaminated packaging	:	Empty remaining contents. Dispose of as unused product. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

DOT	:	Not regulated
TDG	:	Not regulated
IATA	:	

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

Not regulated

IMDG

:

Not regulated

IMDG EmS Number :Not applicable.**ADR**

:

Not regulated

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards**SARA 313** : The following components are subject to reporting levels established by SARA Title III, Section 313:

Galaxolide 1222-05-5

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM1 Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

LSS CLINICAL ANTIPERSPIRANT POWDER

This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

C12-15 ALKYL BENZOATE	68411-27-8
PPG-14 BUTYL ETHER	9003-13-8

Pennsylvania Right To Know

Palm Kernel Oil	8023-79-8
STEARYL ALCOHOL	112-92-5
DECAMETHYLCYCLOPENTASILOXANE	541-02-6
ALUMINUM ZIRCONIUM TETRACHLOROXYDREX GLY	90604-80-1
C12-15 ALKYL BENZOATE	68411-27-8
HYDROGENATED CASTOR OIL	8001-78-3
PEG-8 DISTEARATE	9005-08-7
PPG-14 BUTYL ETHER	9003-13-8

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Admin-

LSS CLINICAL ANTIPERSPIRANT POWDER


This industrial Safety Data Sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product label.

Version	Revision Date:	SDS Number:	Date of last issue: -
1.0	02/20/2025	660000021487	Date of first issue: 02/20/2025

istration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

NFPA 704:



HMIS® IV:

HEALTH	/	1
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Revision Date : 02/20/2025
 US / EN